Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non–small cell lung cancer

Metastatic non–small cell lung cancer (NSCLC) care has been transformed these last few years with the approval of programmed death (ligand)–1 (PD(L)1) blockade [1–5] in frontline and after progression on or after platinum-based chemotherapy. Managing immune-related toxicities has become the new field of expertise for oncologists and guidelines of optimal clinical management for PD(L)1 blockade–treated patients are still being established [6–8].

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2xmeYIT
via IFTTT